MLN Matters Article (New) MM12950: National Coverage Determination 200.3: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
This new Article comprises Subregulatory Guidance for coverage regarding FDA-approved monoclonal antibodies and CMS-approved studies. MLN Matters (MM) Articles are based on information contained within Change Requests (CRs). In this case, this article is based on content within CR12950 that is posted on the CMS website at https://www.cms.gov/files/document/r11692NCD.pdf.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: December 08, 2022
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.